Genetics Co. Perlegen Raises $74M Series D For Pipeline Development

Perlegen Sciences Inc., a start-up that has a platform to determine associations
between common genetic patterns and drug response, said it had closed a $74
million Series D funding round for developing a late-stage drug pipeline.